Literature DB >> 21972208

Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.

Peter Valent.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21972208      PMCID： PMC3186297          DOI： 10.3324/haematol.2011.052076

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

Review 1.  Practical management of patients with chronic myeloid leukemia.

Authors:  Francisco Cervantes; Michael Mauro
Journal:  Cancer       Date:  2011-03-16       Impact factor: 6.860

2.  Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.

Authors:  Massimo Breccia; Roberto Latagliata; Fabio Stagno; Luigiana Luciano; Antonella Gozzini; Fausto Castagnetti; Carmen Fava; Francesco Cavazzini; Mario Annunziata; Antonella Russo Rossi; Patrizia Pregno; Elisabetta Abruzzese; Paolo Vigneri; Giovanna Rege-Cambrin; Simona Sica; Fabrizio Pane; Valeria Santini; Giorgina Specchia; Gianantonio Rosti; Giuliana Alimena
Journal:  Haematologica       Date:  2011-06-17       Impact factor: 9.941

3.  New tyrosine kinase inhibitors in chronic myeloid leukemia.

Authors:  Giovanni Martinelli; Simona Soverini; Gianantonio Rosti; Daniela Cilloni; Michele Baccarani
Journal:  Haematologica       Date:  2005-04       Impact factor: 9.941

4.  Severe peripheral arterial disease during nilotinib therapy.

Authors:  Philipp Le Coutre; Delphine Rea; Elisabetta Abruzzese; Hervé Dombret; Malgorzata M Trawinska; Susanne Herndlhofer; Bernd Dörken; Peter Valent
Journal:  J Natl Cancer Inst       Date:  2011-08-02       Impact factor: 13.506

5.  Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Susan O'brien; Gautham Borthakur; John Bruzzi; Reginald Munden; Jorge Cortes
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

6.  Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.

Authors:  Karl J Aichberger; Susanne Herndlhofer; Gerit-Holger Schernthaner; Martin Schillinger; Gerlinde Mitterbauer-Hohendanner; Christian Sillaber; Peter Valent
Journal:  Am J Hematol       Date:  2011-04-27       Impact factor: 10.047

7.  The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils.

Authors:  Michael Kneidinger; Uwe Schmidt; Uwe Rix; Karoline V Gleixner; Anja Vales; Christian Baumgartner; Christian Lupinek; Margit Weghofer; Keiryn L Bennett; Harald Herrmann; Alexandra Schebesta; Wayne R Thomas; Susanne Vrtala; Rudolf Valenta; Francis Y Lee; Wilfried Ellmeier; Giulio Superti-Furga; Peter Valent
Journal:  Blood       Date:  2008-01-07       Impact factor: 22.113

8.  Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.

Authors:  Thomas O'Hare; Christopher A Eide; Michael W N Deininger
Journal:  Blood       Date:  2007-05-11       Impact factor: 22.113

9.  Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib.

Authors:  M Breccia; M Muscaritoli; F Gentilini; R Latagliata; I Carmosino; F Rossi Fanelli; G Alimena
Journal:  Leuk Res       Date:  2007-03-26       Impact factor: 3.156

10.  Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

Authors:  Uwe Rix; Oliver Hantschel; Gerhard Dürnberger; Lily L Remsing Rix; Melanie Planyavsky; Nora V Fernbach; Ines Kaupe; Keiryn L Bennett; Peter Valent; Jacques Colinge; Thomas Köcher; Giulio Superti-Furga
Journal:  Blood       Date:  2007-08-24       Impact factor: 22.113
View more
  16 in total

1.  Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.

Authors:  Wolfgang R Sperr; Thomas Pfeiffer; Gregor Hoermann; Susanne Herndlhofer; Christian Sillaber; Christine Mannhalter; Michael Kundi; Peter Valent
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

Review 2.  Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.

Authors:  Peter Valent; Emir Hadzijusufovic; Gregor Hoermann; Wolfgang Füreder; Gerit-Holger Schernthaner; Wolfgang R Sperr; Rudolf Kirchmair; Dominik Wolf
Journal:  Leuk Res       Date:  2017-05-12       Impact factor: 3.156

Review 3.  From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview.

Authors:  Carlo Gabriele Tocchetti; Christian Cadeddu; Daniela Di Lisi; Saveria Femminò; Rosalinda Madonna; Donato Mele; Ines Monte; Giuseppina Novo; Claudia Penna; Alessia Pepe; Paolo Spallarossa; Gilda Varricchi; Concetta Zito; Pasquale Pagliaro; Giuseppe Mercuro
Journal:  Antioxid Redox Signal       Date:  2017-05-15       Impact factor: 8.401

4.  Pericardial Effusion Secondary to Nilotinib in an Elderly Patient With Chronic Myelogenous Leukemia.

Authors:  Geetika Arora; Paulus Adinugraha; Amna Aijaz; Alvaro Vargas Pelaez; Maurice Rachko
Journal:  Cureus       Date:  2022-04-05

5.  A critical history of chromic myeloid leukemia.

Authors:  Michele Baccarani; Fabrizio Pane
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-01-02       Impact factor: 2.576

6.  BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature.

Authors:  Matthew J Durand; Shelby N Hader; Alexa Derayunan; Natalya Zinkevich; Jennifer J McIntosh; Andreas M Beyer
Journal:  Microcirculation       Date:  2020-09-05       Impact factor: 2.628

Review 7.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113

8.  Clinical cardiac safety profile of nilotinib.

Authors:  Theo D Kim; Philipp le Coutre; Michaela Schwarz; Peggy Grille; Michal Levitin; Suzanne Fateh-Moghadam; Francis J Giles; Bernd Dörken; Wilhelm Haverkamp; Clemens Köhncke
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

9.  Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome.

Authors:  Agnieszka Piekarska; Lidia Gil; Witold Prejzner; Piotr Wiśniewski; Aleksandra Leszczyńska; Michał Gniot; Mieczysław Komarnicki; Andrzej Hellmann
Journal:  Ann Hematol       Date:  2015-07-29       Impact factor: 3.673

10.  Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment.

Authors:  D Russo; M Malagola; C Skert; V Cancelli; D Turri; P Pregno; M Bergamaschi; M Fogli; N Testoni; A De Vivo; F Castagnetti; E Pungolino; F Stagno; M Breccia; B Martino; T Intermesoli; G R Cambrin; G Nicolini; E Abruzzese; M Tiribelli; C Bigazzi; E Usala; S Russo; A Russo-Rossi; M Lunghi; M Bocchia; A D'Emilio; V Santini; M Girasoli; R Di Lorenzo; S Bernardi; A Di Palma; B M Cesana; S Soverini; G Martinelli; G Rosti; M Baccarani
Journal:  Blood Cancer J       Date:  2015-09-18       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.